Craig Amanda J, Housley Gary D
Translational Neuroscience Facility & Department of Physiology, School of Medical Sciences, University of New South Wales, Sydney NSW, Australia.
Front Mol Neurosci. 2016 May 24;9:34. doi: 10.3389/fnmol.2016.00034. eCollection 2016.
Stroke is a leading cause of death and disability, with a lack of treatments available to prevent cell death, regenerate damaged cells and pathways, or promote neurogenesis. The extended period of hours to weeks over which tissue damage continues to occur makes this disorder a candidate for gene therapy. This review highlights the development of gene therapy in the area of stroke, with the evolution of viral administration, in experimental stroke models, from pre-injury to clinically relevant timeframes of hours to days post-stroke. The putative therapeutic proteins being examined include anti-apoptotic, pro-survival, anti-inflammatory, and guidance proteins, targeting multiple pathways within the complex pathology, with promising results. The balance of findings from animal models suggests that gene therapy provides a viable translational platform for treatment of ischemic brain injury arising from stroke.
中风是导致死亡和残疾的主要原因,目前缺乏可用于预防细胞死亡、使受损细胞和神经通路再生或促进神经发生的治疗方法。组织损伤持续数小时至数周的较长时间,使得这种疾病成为基因治疗的候选对象。本综述重点介绍了中风领域基因治疗的发展情况,以及在实验性中风模型中,从损伤前到中风后数小时至数天的临床相关时间范围内病毒给药方式的演变。正在研究的假定治疗性蛋白质包括抗凋亡、促生存、抗炎和导向蛋白,它们针对复杂病理过程中的多种途径,取得了令人鼓舞的结果。动物模型的研究结果表明,基因治疗为治疗中风引起的缺血性脑损伤提供了一个可行的转化平台。